TRANSITION THERAPEUTICS
Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include ELND005 for the treatment of Alzheimer's disease and TT223 for the treatment of diabetes. Transition has an emerging pipeline of preclinical drug candidates acquired externally and developed internally using its proprietary drug discovery engine.
TRANSITION THERAPEUTICS
Industry:
Biopharma Biotechnology Therapeutics
Founded:
1987-01-01
Address:
Toronto, Ontario, Canada
Country:
Canada
Website Url:
http://www.transitiontherapeutics.com
Total Employee:
11+
Status:
Closed
Contact:
416-260-7770
Email Addresses:
[email protected]
Total Funding:
41.8 M USD
Technology used in webpage:
SPF Network Solutions DNS AppRiver
Current Employees Featured
Founder
Stock Details
Investors List
Oracle Investment Management Inc.
Oracle Investment Management Inc. investment in Post-IPO Equity - Transition Therapeutics
Jack W. Schuler Living Trust
Jack W. Schuler Living Trust investment in Post-IPO Equity - Transition Therapeutics
Larry N. Feinberg
Larry N. Feinberg investment in Post-IPO Equity - Transition Therapeutics
Larry N. Feinberg
Larry N. Feinberg investment in Post-IPO Equity - Transition Therapeutics
Official Site Inspections
http://www.transitiontherapeutics.com
Unable to get host informations!!!
